Skip to content

WHWK WHWK Other Commercial Liabilities

Other Commercial Liabilities at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
CytomX Therapeutics logo
CytomX TherapeuticsCTMX

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's other commercial liabilities?
WHWK (WHWK) reported other commercial liabilities of $9.31M in Q1 2026.
How has WHWK's other commercial liabilities changed year-over-year?
WHWK's other commercial liabilities increased by 8.1% year-over-year, from $8.62M to $9.31M.
What is the long-term trend for WHWK's other commercial liabilities?
Over 4 years (2021 to 2025), WHWK's other commercial liabilities has grown at a 11.8% compound annual growth rate (CAGR), from $8.7M to $13.6M.